Edgewise Therapeutics, Inc.
EWTXEdgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule precision medicines for serious muscle diseases.
Earnings
Next report
Aug 6, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule precision medicines for serious muscle diseases. The company utilizes a proprietary drug discovery platform to identify sarcomere modulators that regulate key proteins in muscle tissue to address rare neuromuscular and cardiac conditions. Their core value proposition lies in protecting muscle fibers from contraction-induced injury and improving cardiac relaxation without compromising systolic function.
A clinical-stage innovator with a first-in-class mechanism for Becker muscular dystrophy and a differentiated cardiac profile that avoids the ejection fraction risks of existing cardiac myosin inhibitors.
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s market cap?
- Edgewise Therapeutics, Inc. (EWTX) has a market capitalization of $4.5B and trades on NASDAQ.
- Who are Edgewise Therapeutics, Inc.'s competitors?
- Edgewise Therapeutics, Inc.'s key competitors include Dyne Therapeutics, Avidity Biosciences, Cytokinetics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Edgewise Therapeutics, Inc. partner with?
- Edgewise Therapeutics, Inc.'s notable partners include GRASP-LGMD Consortium.
- Where is Edgewise Therapeutics, Inc. headquartered?
- Edgewise Therapeutics, Inc. is headquartered in United States of America and employs approximately 92 people. It has been publicly traded since 2021.